Morris Arlene
Morris Arlene, DIR, reported a transaction classified as exercise at Cogent Biosciences, Inc. involving 3583.000000 shares for an estimated $0.00. Reported holdings after the transaction were 0.000000 shares. The stored filing text includes a detected 10b5-1 reference.
- Trade date
- Aug 27, 2026
- Filing date
- Aug 31, 2026
How reported position traded is calculated
Not calculated for derivative securities.
Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.
COGT price since this filing
Daily closing prices, with the filing date and available return windowsTransaction facts
Stored Form 4 columns with their raw values
- Type
- exercise Code M
- Identifier
- 0001193125-26-377001 Stock Option (Right to Buy)
- Transaction date
- Aug 27, 2026 Filed Aug 31, 2026, 09:01 PM · 4d delay
- Shares
- 3,583 sh $0.00 per share
- Estimated value
- $0 Computed from shares × price
- Holdings after
- 0 sh Direct
Filing signal explanations
Badges describe filing facts only — not predictions.
-20 points
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a meaningfully negative filing-only score. It is likely less useful as a positive insider-activity signal.
How this score is calculated
- direct_ownership+6 points
direct_or_indirect_ownership = D
Direct ownership reports the insider's personal stake. - derivative_transaction-16 points
is_derivative = true
Derivative exercise rows are less discretionary than open-market purchases. - tenb5_1_detected-10 points
is_10b5_1 = true
Stored filing content includes detected 10b5-1 language.
Signed filing-only points, not a probability or expected return. Version v1.
Reported relationships & other filings
Form 4 relationship flags and nearby filing context
No officer title
- F1
Transactions effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 28, 2026.
- F2
The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $36.46 to $37.45. Upon request by the staff of the U.S. Se…
- F3
The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $37.46 to $37.65. Upon request by the staff of the U.S. Se…
- F4
These options are fully vested.
0 other transactions
0 recent txs